Procept Biorobotics
PRCT
About: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Employees: 756
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
91% more call options, than puts
Call options by funds: $15.5M | Put options by funds: $8.09M
48% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 82
4.36% more ownership
Funds ownership: 92.01% [Q1] → 96.38% (+4.36%) [Q2]
5% more capital invested
Capital invested by funds: $2.94B [Q1] → $3.07B (+$132M) [Q2]
4% less funds holding
Funds holding: 277 [Q1] → 267 (-10) [Q2]
18% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 40
44% less funds holding in top 10
Funds holding in top 10: 9 [Q1] → 5 (-4) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
|
Oppenheimer
Suraj Kalia
|
$60
|
Outperform
Upgraded
|
2 Sep 2025 |
|
Wells Fargo
Nathan Treybeck
|
$58
|
Overweight
Maintained
|
7 Aug 2025 |
|
Piper Sandler
Matt OBrien
|
$55
|
Overweight
Maintained
|
7 Aug 2025 |
|
Morgan Stanley
Patrick Wood
|
$68
|
Overweight
Maintained
|
15 Jul 2025 |
Financial journalist opinion
